Report: How 10 top new technologies will help world reach globally-agreed goals by 2015

October 07, 2004

New medical tools that quickly and accurately diagnose diseases like AIDS and malaria top a list of 10 biotech breakthroughs deemed most important for improving health in developing countries within the decade, science that will dramatically move the world towards its Millennium Development Goals for 2015, according to scientists and ethicists in a major new report to the United Nations.

Newly emerged diagnostic tools detect illness at a molecular level in blood or tissues -- thus improving a patient's chance of survival, conserving scarce resources in poor countries now wasted on inappropriate treatments, and better containing disease outbreaks, according to Genomics and Global Health, being launched Oct. 7 at the 4th World Conference of Science Journalists in Montreal.

Prepared for the Science, Technology and Innovation Task Force of the UN Millennium Project, the report calls for a global institute to share and promote the health and environmental benefits being created through genomic sciences - and thereby save tens of millions of lives per year in developing countries.

"Imagine a world in which a doctor in the poorest country can instantly diagnose tuberculosis or malaria, or provide women a way they can prevent HIV-AIDS; where bad water is made safe again. This report is about the pathways to get there," says report co-author Peter Singer, MD, Director of the University of Toronto Joint Centre for Bioethics.

The list of top 10 of biotechnologies for improving health in developing countries represents a consensus of 28 eminent scientists canvassed separately in developing and developed countries.

The report details dozens of specific health-improvement applications the 10 new technologies have today and are expected to produce in future.

Examples include sequencing the genomes of parasites responsible for most of the world's human malaria, as well as the mosquito that carries it. Knowledge of these genomes, paired with the knowledge of the human genome, can be used to develop new drugs and vaccines.

As well, the report forecasts the creation of microbicides for female-controlled protection against sexually transmitted disease like HIV, both with and without contraceptive effect.

The report maps the top 10 new biotechnologies against the UN Millennium Development Goals, established by world leaders in 2000 for achievement by 2015. It then predicts the extent to which the new science will drive progress towards five of the eight globally agreed objectives:

  • Promote gender equality and empower women;
  • Reduce child mortality;
  • Improve maternal health;
  • Combat HIV, malaria and other diseases; and
  • Ensure environmental sustainability.

    If not properly harnessed, the experts warn, the breakthroughs being produced through genomics will dramatically widen rather than narrow the gap between developed and developing countries.

    "Millions of people in developing countries die each year from diseases that could be prevented or treated cheaply and easily through the development and use of a handful of biotechnologies," says Dr. Singer. "This report is about reaching the UN's Millennium Development Goals (MDGs), mobilizing the developed countries of the world to share its wealth of information and know-how, and supporting the innovation of developing countries."

    10 Promising New Technologies Can Help World Achieve Its MDGs

    Funded by Genome Canada's GE3LS program and others , the report details the potential contribution of genomics and related biotechnologies in achieving five of the eight MDGs.

    It notes genomics-related technologies, including DNA sequencing and bioinformatics, once so costly only wealthy nations could afford them, are now becoming available to many in developing countries. Some applications are now so simple and cheap they can start replacing older, cumbersome, time-consuming and expensive health care technologies in poorer countries.

    The 10 most promising cutting-edge technologies for health in developing countries:

  • Easy-to-use molecular diagnostic tests for TB, hepatitis C, HIV-AIDS, malaria and other diseases, which detect the presence or absence of pathogen-associated molecules, such as DNA or protein, in a patient's blood or tissues;

  • Recombinant vaccines against infectious diseases, produced through genetic engineering, which promise to be safer, cheaper and possibly easier to store and transport than traditional vaccines;

  • Reducing pollution and making water safe to drink through bioremediation - the potential exploitation of micro-organisms with remarkable biochemical properties;

  • Creating microbicides for female-controlled protection against sexually transmitted disease like HIV, both with and without contraceptive effect;

  • Better drug and vaccine delivery methods that avoid the use of needles and reduce cross contamination;

  • Bioinformatics to identify drug targets and to examine pathogen-host interactions;

  • Nutrition-enriched crops to counter specific deficiencies, such as vitamin A-rich "Golden Rice" to improve health for millions without a balanced diet;

  • Sequencing pathogen genomes to understand their biology and identify new antimicrobials;

  • Recombinant technology to make therapeutic products (e.g. insulin, interferons) more affordable to help fight such diseases as diabetes, now emerging as a major public health problem throughout the world;

  • Combinatorial chemistry for drug discovery.

    "In the long run such emerging technologies tend to help people in developing countries more than in developed countries," says co-author Abdallah S. Daar, MD, co-director of the Canadian Program on Genomics and Global Health at the JCB.

    "A good example is vaccines, which have always depended on biotechnology and were initially expensive, but in the end helped save millions of lives in the developing world where the majority of humanity lives. With a commitment to international cooperation and a relatively modest financial investment, we can make substantial gains in the battle against a suite of the world's deadliest diseases."

    Global Genomics Initiative

    "Every year 11 million children die before reaching their 5th birthday," says co-author Elizabeth Dowdeswell, former UN Under Secretary-General and Executive Director of the UN Environment Programme. "Recent rapid advances in genomics and related biotechnologies offer radically improved tools to help remedy such global tragedies. But either they're not being used or they're not accessible.

    "We need a governance mechanism that fosters a balance between the global public goods characteristics of genomics knowledge and the private goods nature of its application."

    The report calls for creation of a Global Genomics Initiative (GGI), promoting genomics as a "global public good" and enlisting governments, private companies and other organizations from developed and developing countries alike to support genomics research and learning worldwide.

    The GGI would give developing countries access to knowledge essential to their reaping the benefits of genomics for development. It would promote actions needed at a global level, strengthen capacity in biotechnology worldwide by increasing the international exchange of know-how, and encourage partnerships between countries.

    Key Actors: Developing Countries Themselves

    "Countries such as India, China, Cuba and Brazil that already have genomics and health biotech capacity set the example for others are best positioned to take advantage of the genomics revolution," says co-author Halla Thorsteinsdottir.

    Cuba, for example, has invested heavily since the 1980's in research infrastructure and manufacturing in biotechnology. The country has produced several successful products, including the world's only Meningitis B vaccine. It also holds at least 400 patents in the biotechnology field. The biotechnology sector has already contributed towards improved health in the country and is poised to become a major export industry in Cuba.

    The report says education is key to creating National Systems of Innovation (NSIs) in biotechnology in developing countries and active research and commercialisation of research are needed to promote sustainable development in this field. These countries need to:

  • Re-energize academic institutions and public sector research to strengthen their science base;
  • Train people to use, adapt and innovate biotechnologies;
  • Encourage regional and international cooperation to exchange knowledge;
  • Improve the policy environment (including intellectual property laws and regulation);
  • Foster private sector growth, encouraging it to address local health needs, and strengthening linkages between public and private sectors to create new biotechnology goods and services.

    Says co-author Tara Acharya: "With this report we try to illustrate the importance of investing in new tools for health and development in order to complement existing technologies and energize the field of global health."

    The report says most governments in developing countries and the international donor community have seriously underestimated the value of investing in health. The Commission on Macroeconomics and Health estimates that approximately 330 million disability-adjusted life years (one disability-adjusted life-year is defined as the loss of one year of healthy life to disease) could be saved for every 8 million deaths prevented, generating economic benefit of US$186 billion per year as of 2015. This would require additional annual health outlays, for all low-income countries and selected middle-income countries, of US $57 billion by 2007 and US $94 billion by 2015."

    Harvard University professor Calestous Juma, Co-ordinator of the Task Force on Science, Technology and Innovation of the UN Millennium Project commissioned by Secretary-General Kofi Annan, called the contribution "a pioneering report that will shape the way leaders around the world think about the role of new technologies in solving old problems. Its clarity is only matched by its practical approach."
    Appendix 1

    Genomics and related biotechnologies can support the MDGs

    Millennium Development Goal Statistics/Facts

    Goal 3: Promote gender equality and empower women.

    In 2001 55% of HIV cases in sub-Saharan Africa were women. Average HIV infection rates in teenage girls are five times higher than those in teenage boys.

    Biotechnology to address MDG
  • Female control over sexually transmitted diseases (STD) protection.
  • Vaccine and drug delivery.

    Goal 4: Reduce child mortality. About 11 million children die before reaching their fifth birthday.

    Biotechnology to address MDG
  • Molecular Diagnostics.
  • Vaccine and drug delivery.
  • Recombinant vaccines.
  • Female control over STD transmission protection.
  • Nutritionally enriched genetically modified (GM) crops.
  • Combinatorial chemistry.

    Goal 5: Improve maternal health. Over 500,000 maternal deaths per year.

    Biotechnology to address MDG
  • Molecular Diagnostics.
  • Vaccine and drug delivery.
  • Recombinant vaccines.
  • Female control over STD transmission protection.
  • Nutritionally enriched GM crops.
  • Combinatorial chemistry.

    Goal 6: Combat HIV, malaria and other diseases. HIV/AIDS, malaria and TB responsible for about 40% (5 million) of all deaths in developing world. In 2002, 3.1 million people died of AIDS, 2 million of TB, over 1 million of malaria.

    Biotechnology to address MDG
  • Molecular Diagnostics.
  • Vaccine and drug delivery.
  • Recombinant vaccines.
  • Female control over STD transmission protection.
  • Bioremediation.
  • Sequencing pathogen genomes.
  • Bioinformatics.
  • Enriched GM crops.
  • Combinatorial chemistry.

    Goal 7: Ensure environmental sustainability. 5 million deaths per year attributed to waterborne diseases.

    Biotechnology to address MDG
  • Bioremediation.

    University of Toronto Joint Centre for Bioethics
    Innovative. Interdisciplinary. International.
    Improving health care through bioethics.

    The JCB is a partnership among the University of Toronto and nine hospitals. It provides leadership in bioethics research, education, and clinical activities. Its vision is to be a model of interdisciplinary collaboration in order to create new knowledge and improve practices with respect to bioethics. The JCB does not advocate positions on specific issues, although its individual members may do so.

    The goals of the JCB are:
  • To foster interdisciplinary research and scholarship, link education to research, and disseminate research findings to improve policies and practices.
  • To support undergraduate, graduate and postgraduate educational programs in bioethics.
  • To support clinical ethics activities including continuing education for health care providers, ethics committees, ethics consultation, and projects to address specific issues arising in JCB hospitals.
  • To foster collegial discussion of bioethics issues throughout the JCB participating institutions, and to serve as a resource for the media, policymakers, and community groups.

    For more information:

    University of Toronto Joint Center for Bioethics

    Related Malaria Articles from Brightsurf:

    Clocking in with malaria parasites
    Discovery of a malaria parasite's internal clock could lead to new treatment strategies.

    Breakthrough in malaria research
    An international scientific consortium led by the cell biologists Volker Heussler from the University of Bern and Oliver Billker from the UmeƄ University in Sweden has for the first time systematically investigated the genome of the malaria parasite Plasmodium throughout its life cycle in a large-scale experiment.

    Scientists close in on malaria vaccine
    Scientists have taken another big step forward towards developing a vaccine that's effective against the most severe forms of malaria.

    New tool in fight against malaria
    Modifying a class of molecules originally developed to treat the skin disease psoriasis could lead to a new malaria drug that is effective against malaria parasites resistant to currently available drugs.

    Malaria expert warns of need for malaria drug to treat severe cases in US
    The US each year sees more than 1,500 cases of malaria, and currently there is limited access to an intravenously administered (IV) drug needed for the more serious cases.

    Monkey malaria breakthrough offers cure for relapsing malaria
    A breakthrough in monkey malaria research by two University of Otago scientists could help scientists diagnose and treat a relapsing form of human malaria.

    Getting to zero malaria cases in zanzibar
    New research led by the Johns Hopkins Center for Communication Programs, Ifakara Health Institute and the Zanzibar Malaria Elimination Program suggests that a better understanding of human behavior at night -- when malaria mosquitoes are biting -- could be key to preventing lingering cases.

    Widely used malaria treatment to prevent malaria in pregnant women
    A global team of researchers, led by a research team at the Liverpool School of Tropical Medicine (LSTM), are calling for a review of drug-based strategies used to prevent malaria infections in pregnant women, in areas where there is widespread resistance to existing antimalarial medicines.

    Protection against Malaria: A matter of balance
    A balanced production of pro and anti-inflammatory cytokines at two years of age protects against clinical malaria in early childhood, according to a study led by ISGlobal, an institution supported by ''la Caixa'' Foundation.

    The math of malaria
    A new mathematical model for malaria shows how competition between parasite strains within a human host reduces the odds of drug resistance developing in a high-transmission setting.

    Read More: Malaria News and Malaria Current Events
  • is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to